Tang, Monica http://orcid.org/0000-0003-0075-2176
Joensuu, Heikki
Simes, Robert J.
Price, Timothy J.
Yip, Sonia
Hague, Wendy
Sjoquist, Katrin M.
Zalcberg, John
Funding for this research was provided by:
Cancer Australia (Support for Cancer Clinical Trials Program)
Article History
Received: 26 March 2019
Revised: 30 June 2019
Accepted: 4 July 2019
First Online: 5 August 2019
Competing interests
: M.T. reports non-financial support from Roche, outside the submitted work. H.J. reports personal fees and other from Orion Pharma, personal fees from Orion Pharma, other from Sartar Therapeutics, other from Orion Pharma, personal fees from Neutron Therapeutics, outside the submitted work. K.M.S. reports other from IPSEN and AMGEN, personal fees from PFIZER, and personal fees from MERCK, outside the submitted work. J.Z. is the chair of the Australian Clinical Trials Alliance (ACTA). The views expressed in this paper do not represent those of ACTA. The remaining authors declare no competing interests.
: Not applicable
: This work was supported in part by a National Health and Medical Research Council (NHMRC) Program Grant [grant number 1037786]. M.T. was funded by Support for Cancer Clinical Trials Program from Cancer Australia.
: Not applicable
: Not applicable
: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).